Search
Displaying 941–950 of 1069 results
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
FFB Funding Helps Retinal Genetics Lab Secure $2 Million Investment
Research NewsHow the Foundation Fighting Blindness (FFB) provided timely funding of $155,000 to help a lab at the University of California, San Diego (UCSD), leverage a $2 million retinal-gene discovery project.
-
jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP
Research NewsBased on lab studies, researchers believe the treatment can preserve and potentially rescue the patient’s existing photoreceptors, thereby saving and possibly restoring vision.
-
FFB-CRI Launching Natural History Study for People with USH2A Mutations
Research NewsThe study — known as RUSH2A (“R” stands for “rate of progression”) — is beginning in spring 2017 and will take place at about 20 clinical sites around the world. RUSH2A investigators will use a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.
-
Dr. Eliot Berson, Pioneer in Vitamin A Therapy for Retinitis Pigmentosa, Passes Away
Research NewsDr. Berson dedicated himself to clinical care and vision-saving research for people with inherited retinal diseases for five decades.
-
First Patient Treated in XLRP Gene Therapy Clinical Trial
Research NewsThe Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
-
Unregulated Stem-Cell Therapy Causes Severe Vision Loss for Three Florida Women
Research News“…participation in a study for an emerging therapy that is not regulated by the FDA or another well-recognized regulatory agency like the European Medicines Agency in Europe, is fraught with dangers and can lead to unexpected serious consequences.”
-
FFB Convenes Experts to Discuss Therapeutic Opportunities for Stargardt Disease
Research NewsMuch of the information and data shared during the meeting came out of ProgSTAR, the FFB-CRI-funded natural history study of 365 Stargardt disease patients.
-
AGTC Leverages Funding from the Foundation to Move Promising Treatments into Clinical Trials
Research NewsCompany Builds on FFB’s Initial Investment to Garner $265 Million in Therapy Development Funding
-
Foundation Investing in Drug to Slow Many Forms of RP
Research NewsThe Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has announced an investment of up to $7.5 million to advance the potential therapy into and through a Phase II clinical trial.
